PreludeDx

Let’s take a moment to celebrate our lab manager, Joe, who has been with us for four years. Recently, we asked him why he enjoys coming to work each day. “I thrive on collaborating with people and building something from scratch,” Joe says. “I enjoy creating efficient processes that ultimately benefit the patient.” As the lab manager, Joe appreciates our focus on innovation, including the use of AI and new technologies like multiplex immunofluorescence staining. If you want to be part of a tight-knit, inventive team making a real impact, we encourage you to explore our career opportunities. https://lnkd.in/gM_nEmdx

As #BreastCancerAwarenessMonth wraps up, Jennifer Douglas, a #DCIS survivor, author and patient advocate, shares advice for women who’ve been diagnosed with DCIS: ·     Advocate for yourself ·     Take your time to get your questions answered ·     Make an informed choice about treatment ·     And ask your doctor for #DCISionRT Thank you for sharing your story with us, Jennifer!

We were proud to sponsor Cancer Help Desk’s fundraiser, which brought together healthcare professionals, advocates and industry leaders “who share a common goal of helping cancer patients gain access to biomarker testing and treatments,” says Chris Emery, our Vice President Strategic Marketing and Business Development.   Earlier this year, we formed a partnership with this nonprofit to provide expert nurse navigation services for women diagnosed with #DCIS. These expert navigators close gaps in patient care by answering questions regarding the clinical utility of #DCISionRT, explaining the logistics of the test and reviewing test results.

Family dynamics can change dramatically with a cancer diagnosis. Jennifer Douglas, a #DCIS survivor, author and patient advocate, shares how her #breastcancer diagnosis and treatment impacted her husband and two teenage boys. “We were all well beyond the breaking point!”

Halfway through radiation therapy, Jennifer Douglas, a #DCIS survivor, author and patient advocate, says “my breast looked like I had fallen asleep on a topless beach and forgotten to put sunscreen on.” In this video, Jennifer shares how she dealt with radiation therapy — both physically and emotionally – and what she did to combat its challenging side effects.

During #BreastCancerAwarenessMonth, our team members attended Pink Runway from The Maimonides Breast Cancer Center (Maimonides Medical Center). It was an honor to celebrate #breastcancer survivors and their community, as they shared stories of hope and graced the stage with their beauty and strength. What an inspirational evening!

“My #DCIS was the size of a grain of rice.” Even though it was tiny, it changed Jennifer Douglas’s life — in a big way. As a #DCIS survivor, author and patient advocate, she looks back on her journey and shares why a lumpectomy was the right surgical choice for her.

The day before her 42nd birthday — Jennifer Douglas was diagnosed with #DCIS. In this video, Jennifer, a DCIS survivor, author and patient advocate, reads an excerpt from her book, “A Breast Cancer Journey: Living It One Step At a Time.” In this clip, she talks about what it felt like when she was told she had breast cancer.

We’d like to introduce you to Jennifer Douglas, Author, #DCIS survivor and patient advocate. During #BreastCancerAwareness month, we’ll share videos of her reading excerpts from her book, “A Breast Cancer Journey: Living It One Step At a Time.” Jennifer’s videos are for everyone — her first-hand account helps #breastcancer patients, family members and caregivers understand just what it’s like to go through the diagnosis, treatment and recovery of this disease, and the impact it has on all. Stay tuned.

Our latest study, published in Clinical Breast Cancer, marks a significant advancement for HER2-positive #DCIS patients. Our #DCISionRT test successfully identified two distinct groups of HER2(3+) DCIS patients treated with breast-conserving surgery (BCS) plus radiation therapy (RT). Patients with the newly identified Residual Risk subtype showed significantly higher in-breast recurrence rates (16.2% vs 1.6%, p=.01). And 63% of HER2(3+) patients had the Residual Risk subtype, suggesting an opportunity to refine treatment strategies for those patients. What does this mean? ·     More precise risk stratification for #DCIS patients. ·     Potential for tailored treatments, including the possible benefit of Trastuzumab. ·     Empowering physicians and patients to make more informed decisions about treatment plans. Read more: https://lnkd.in/g-mqqDkx